Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

MEDI4736

- PMLiVE

Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients

Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year

- PMLiVE

AstraZeneca’s Imfinzi/Imjudo regimen recommended by NICE to treat liver cancer

Approximately 6,600 people are diagnosed with liver cancer every year in the UK

- PMLiVE

CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

- PMLiVE

AstraZeneca shares late-stage results for Tagrisso combination in lung cancer

An estimated 2.4 million people globally are diagnosed with lung cancer each year

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway granted FDA accelerated approval for lung cancer

Approximately 226,650 new cases of lung cancer will be diagnosed in the US this year

- PMLiVE

FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer

ROS1-positive non-small cell lung cancer accounts for approximately 2% of new NSCLC cases

- PMLiVE

MHRA approves SFL’s Aumseqa to treat EGFR-mutated lung cancer in adults

Approximately 43,000 people are diagnosed with lung cancer every year in the UK

- PMLiVE

Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC

Up to 55% of patients with non-metastatic NSCLC develop recurrence despite curative resection

- PMLiVE

Johnson & Johnson’s subcutaneous Rybrevant granted EC approval to treat NSCLC

It is hoped that the formulation will improve the treatment experience for patients

- PMLiVE

AstraZeneca’s Imfinzi regimen receives EC approval to treat resectable NSCLC

More than 450,000 people are diagnosed with lung cancer every year in Europe

- PMLiVE

BMS receives positive CHMP opinion for perioperative Opdivo regimen in lung cancer

Up to 55% of non-metastatic NSCLC patients will develop disease recurrence despite surgical resection

- PMLiVE

J&J shares overall survival results for Rybrevant/Lazcluze combination in lung cancer

The regimen was approved by the MHRA earlier this month to treat EGFR-mutated NSCLC

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links